A covalent inhibitor of CDK7, THZ1, selectively targets MYCN-amplified neuroblastoma cells, leading to global suppression of MYCN-dependent transcriptional amplification and sustained growth inhibition of tumors in a mouse model of neuroblastoma (85). This evidence concerns the gene CDK7 and neuroblastoma.